AG-221 (Enasidenib)

製品コードS8205 バッチS820502

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₁₉H₁₇F₆N₇O
	分子量	473.38	CAS No.	1446502-11-9
Solubility (25°C)*	体外	DMSO	94 mg/mL (198.57 mM)
		Ethanol	94 mg/mL (198.57 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Enasidenib (AG-221)は、IC50が12nMの、IDH2変異酵素に対するファーストインクラスの経口強力可逆的選択的阻害剤です。
in vitro	Enasidenib (AG-221) has been demonstrated to reduce 2-HG levels by >90% and reverse histone and deoxyribonucleic acid (DNA) hypermethylation in vitro, and to induce differentiation in leukemia cell models.
in vivo	Enasidenib (AG-221) is able to potently reduce 2HG found in the bone marrow, plasma and urine of engrafted mice. Treatment with this compound also induced a dose dependent, statistically significant, survival benefit. A proliferative burst of the human specific CD45+ blast cells is followed by cellular differentiation as measured by the expression of CD11b, CD14 and CD15 and cell morphology after its administration. It also restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression and reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Clinical trials combining IDH2 inhibitors with other targeted AML therapies are warranted in order to increase therapeutic efficacy.

製品説明

Enasidenib (AG-221)は、IC50が12nMの、IDH2変異酵素に対するファーストインクラスの経口強力可逆的選択的阻害剤です。

in vitro

Enasidenib (AG-221) has been demonstrated to reduce 2-HG levels by >90% and reverse histone and deoxyribonucleic acid (DNA) hypermethylation in vitro, and to induce differentiation in leukemia cell models.

in vivo

Enasidenib (AG-221) is able to potently reduce 2HG found in the bone marrow, plasma and urine of engrafted mice. Treatment with this compound also induced a dose dependent, statistically significant, survival benefit. A proliferative burst of the human specific CD45+ blast cells is followed by cellular differentiation as measured by the expression of CD11b, CD14 and CD15 and cell morphology after its administration.

It also restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression and reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Clinical trials combining IDH2 inhibitors with other targeted AML therapies are warranted in order to increase therapeutic efficacy.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	OE19 cells
	濃度	5 μM
	反応時間	24 h
	実験の流れ	Different concentrations of Enasidenib (AG-221) were used to treat cells.
動物実験	動物モデル	Murine models of IDH2-mutant leukemia
	投薬量	10 mg/kg or 100 mg/kg bid
	投与方法	--

参考

http://www.bloodjournal.org/content/124/21/437
http://cancerres.aacrjournals.org/content/74/19_Supplement/3116
https://pubmed.ncbi.nlm.nih.gov/36153371/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Adenylate cyclase 10 promotes brown adipose tissue thermogenesis [ iScience, 2025, 28(2):111833]	PubMed: 39949963
Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors [ iScience, 2024, 27(10):110862]	PubMed: 39319271
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect [ Hematol Oncol, 2024, 42(6):e3316]	PubMed: 39526588
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability [ Cancer Discov, 2023, 13(2):496-515]	PubMed: 36355448
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia [ Nat Commun, 2023, 14(1):5709]	PubMed: 37726279
Succinate mediates inflammation-induced adrenocortical dysfunction [ Elife, 2023, 12e83064]	PubMed: 37449973
Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells [ Cancer Sci, 2023, 10.1111/cas.15994]	PubMed: 37882467
Generación de una plataforma para la producción de células CAR-T alogénicas: estudios de eficacia y seguridad [ University of Granada, 2023, ]	PubMed: None
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia [ Nat Commun, 2022, 13(1):6226]	PubMed: 36266272
Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition [ Oncogene, 2022, 41(43):4808-4822]	PubMed: 36153371

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。